Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL
NCT05515406 · View on ClinicalTrials.gov ↗
Study Summary
This is a Phase 1, open-label, multicenter study. This will be the first-in-human clinical study for ONO-7018 and will be conducted in two phases: a Dose Escalation Phase (Part 1) and a Dose Expansion Phase (Part 2).
Conditions Studied
Interventions
- DRUG ONO-7018
Study Locations (10)
Pennsylvania
- University of Pennsylvania — Philadelphia
- Thomas Jefferson University — Philadelphia
Texas
- Baylor Scott & White Research Institute — Dallas
- MD Anderson Cancer Center — Houston
California
- Jonsson Comprehensive Cancer Center — Santa Monica
Missouri
- AMR Kansas City — Kansas City
North Carolina
- Leo Jenkins Cancer Center/ECU School of Medicine — Greenville
Ohio
- University of Cincinnati — Cincinnati
Tennessee
- Sarah Cannon Research Institute — Nashville
Washington
- Northwest Medical Specialities — Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2023-02-13 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05515406
The ClinicalTrials.gov registry entry for NCT05515406 describes a study currently listed as active not recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ono Pharmaceutical Co., which has 37 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Lymphoma, Non-Hodgkin appearing as the primary indexed condition, and to 1 intervention — of which ONO-7018 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05515406 reports 10 study locations spanning 8 distinct geographic areas — top geographies include Pennsylvania, Texas, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05515406 about?
NCT05515406 is a clinical study titled "A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL". This is a Phase 1, open-label, multicenter study. This will be the first-in-human clinical study for ONO-7018 and will be conducted in two phases: a Dose Escalation Phase (Part 1) and a Dose Expansion Phase (Part 2).
What is the current status of trial NCT05515406?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 108 participants. The study started on 2023-02-13. Estimated completion is 2027-12.
What conditions does trial NCT05515406 study?
This clinical trial studies the following conditions: Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05515406?
The interventions under investigation include: ONO-7018 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05515406?
This trial is sponsored by Ono Pharmaceutical Co., which has 37 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05515406 being conducted?
This trial has 10 study locations across California, Missouri, North Carolina, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.